Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Zika Virus | Research article

Immune reactivity to Trypanosoma cruzi chimeric proteins for Chagas disease diagnosis in immigrants living in a non-endemic setting

Authors: Eva Dopico, Rodrigo Pimenta Del-Rei, Bertha Espinoza, Itziar Ubillos, Nilson Ivo Tonin Zanchin, Elena Sulleiro, Zaira Moure, Paola Alejandra Fiorani Celedon, Wayner Vieira Souza, Edimilson Domingos da Silva, Yara Miranda Gomes, Fred Luciano Neves Santos

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Chronic Chagas Disease (CD) diagnosis is based on serological methods employing crude, semipurified or recombinant antigens, which may result in low sensitivity or cross-reactivity. To reduce these restrictions, we developed a strategy involving use of molecules containing repetitive fragments of Trypanosoma cruzi conserved proteins. Diagnostic performance of IBMP-8.1 and IBMP-8.4 chimeric antigens (Molecular Biology Institute of Paraná - IBMP in Portuguese acronym) was assessed to diagnose T. cruzi-infected and non-infected immigrants living in Barcelona (Spain), a non-endemic setting for Chagas disease.

Methods

Reactivity of IBMP-8.1 and IBMP-8.4 was assessed using an in-house automated ELISA with 347 positive and 331 negative individuals to Chagas disease. Antigenic cross-reactivity was measured with sera samples from pregnant women with Toxoplasma gondii (n = 98) and Zika virus (n = 75) antibodies.

Results

The area under the curve values was 1 and 0.99 for the IBMP-8.1 and IBMP-8.4 proteins, respectively, demonstrating excellent diagnostic accuracy. The reactivity index was higher for IBMP-8.1 than IBMP-8.4 in positive samples and no significant difference in reactivity index was observed in negative samples. Sensitivity ranged from 99.4% for IBMP-8.1 to 99.1% for IBMP-8.4 and was not statistically different. Specificity for IBMP-8.1 reached 100 and 99.7% for IBMP-8.4, both nearly 100% accurate. No antigenic cross-reactivity was observed and reactivity index was similar to that for negative Chagas disease individuals.

Conclusions

Our results showed an outstanding performance of IBMP-8.1 and IBMP-8.4 chimeric antigens by ELISA and suggest both chimeric antigens could also be used for Chagas disease diagnosis in immigrants living in non-endemic settings.
Literature
1.
go back to reference Hotez PJ, Dumonteil E, Woc-Colburn L, Serpa JA, Bezek S, Edwards MS, et al. Chagas disease: “the new HIV/AIDS of the Americas”. PLoS Negl Trop Dis. 2012;6(5):e1498.CrossRef Hotez PJ, Dumonteil E, Woc-Colburn L, Serpa JA, Bezek S, Edwards MS, et al. Chagas disease: “the new HIV/AIDS of the Americas”. PLoS Negl Trop Dis. 2012;6(5):e1498.CrossRef
2.
go back to reference World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015;90(6):33–43. World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015;90(6):33–43.
3.
go back to reference Global Burden of Disease Study 2013 Collaborators, Collaborators GB of DS 2013. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800.CrossRef Global Burden of Disease Study 2013 Collaborators, Collaborators GB of DS 2013. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800.CrossRef
4.
go back to reference Soriano Arandes A, Muñoz Gutierrez J, Vergés Navarro M, Castells Doménech C, Portús Vinyeta M, Gascón Brustenga J. Prevalence of Chagas disease in the Latin American immigrant population in a primary health Centre in Barcelona (Spain). Acta Trop. 2009;112(2):228–30.CrossRef Soriano Arandes A, Muñoz Gutierrez J, Vergés Navarro M, Castells Doménech C, Portús Vinyeta M, Gascón Brustenga J. Prevalence of Chagas disease in the Latin American immigrant population in a primary health Centre in Barcelona (Spain). Acta Trop. 2009;112(2):228–30.CrossRef
5.
go back to reference Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S, et al. Chagas disease and transfusion medicine: a perspective from non-endemic countries. Blood Transfus. 2015;13(4$):540–50. Angheben A, Boix L, Buonfrate D, Gobbi F, Bisoffi Z, Pupella S, et al. Chagas disease and transfusion medicine: a perspective from non-endemic countries. Blood Transfus. 2015;13(4$):540–50.
6.
go back to reference Pane S, Giancola ML, Piselli P, Corpolongo A, Repetto E, Bellagamba R, et al. Serological evaluation for Chagas disease in migrants from Latin American countries resident in Rome, Italy. BMC Infect Dis. 2018;18(1):212.CrossRef Pane S, Giancola ML, Piselli P, Corpolongo A, Repetto E, Bellagamba R, et al. Serological evaluation for Chagas disease in migrants from Latin American countries resident in Rome, Italy. BMC Infect Dis. 2018;18(1):212.CrossRef
7.
go back to reference Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O. Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol. 2014;103(1):1–10.CrossRef Strasen J, Williams T, Ertl G, Zoller T, Stich A, Ritter O. Epidemiology of Chagas disease in Europe: many calculations, little knowledge. Clin Res Cardiol. 2014;103(1):1–10.CrossRef
10.
go back to reference Zingales B. Trypanosoma cruzi genetic diversity: something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Trop. 2018;184:38–52.CrossRef Zingales B. Trypanosoma cruzi genetic diversity: something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity. Acta Trop. 2018;184:38–52.CrossRef
11.
go back to reference Camussone C, Gonzalez V, Belluzo MS, Pujato N, Ribone ME, Lagier CM, et al. Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis. Clin Vaccine Immunol. 2009;16(6):899–905.CrossRef Camussone C, Gonzalez V, Belluzo MS, Pujato N, Ribone ME, Lagier CM, et al. Comparison of recombinant Trypanosoma cruzi peptide mixtures versus multiepitope chimeric proteins as sensitizing antigens for immunodiagnosis. Clin Vaccine Immunol. 2009;16(6):899–905.CrossRef
12.
go back to reference Hernández P, Heimann M, Riera C, Solano M, Santalla J, Luquetti AO, et al. Highly effective serodiagnosis for Chagas’ disease. Clin Vaccine Immunol. 2010;17(10):1598–604.CrossRef Hernández P, Heimann M, Riera C, Solano M, Santalla J, Luquetti AO, et al. Highly effective serodiagnosis for Chagas’ disease. Clin Vaccine Immunol. 2010;17(10):1598–604.CrossRef
13.
go back to reference Houghton RL, Benson DR, Reynolds LD, McNeill PD, Sleath PR, Lodes MJ, et al. A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera. J Infect Dis. 1999;179(5):1226–34.CrossRef Houghton RL, Benson DR, Reynolds LD, McNeill PD, Sleath PR, Lodes MJ, et al. A multi-epitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in radioimmunoprecipitation-confirmed and consensus-positive sera. J Infect Dis. 1999;179(5):1226–34.CrossRef
14.
go back to reference Mucci J, Carmona SJ, Volcovich R, Altcheh J, Bracamonte E, Marco JD, et al. Next-generation ELISA diagnostic assay for Chagas disease based on the combination of short peptidic epitopes. PLoS Negl Trop Dis. 2017;11(10):e0005972.CrossRef Mucci J, Carmona SJ, Volcovich R, Altcheh J, Bracamonte E, Marco JD, et al. Next-generation ELISA diagnostic assay for Chagas disease based on the combination of short peptidic epitopes. PLoS Negl Trop Dis. 2017;11(10):e0005972.CrossRef
15.
go back to reference Santos FL, Celedon PA, Zanchin NI, Souza WV, Silva ED, Foti L, et al. Accuracy of chimeric proteins in the serological diagnosis of chronic Chagas disease - a phase II study. PLoS Negl Trop Dis. 2017;11(3):e0005433.CrossRef Santos FL, Celedon PA, Zanchin NI, Souza WV, Silva ED, Foti L, et al. Accuracy of chimeric proteins in the serological diagnosis of chronic Chagas disease - a phase II study. PLoS Negl Trop Dis. 2017;11(3):e0005433.CrossRef
16.
go back to reference Santos FL, Campos AC, Amorim LD, Silva ED, Zanchin NI, Celedon PA, et al. Highly accurate chimeric proteins for the serological diagnosis of chronic Chagas disease: a latent class analysis. Am J Trop Med Hyg. 2018;99(5):1174–9.CrossRef Santos FL, Campos AC, Amorim LD, Silva ED, Zanchin NI, Celedon PA, et al. Highly accurate chimeric proteins for the serological diagnosis of chronic Chagas disease: a latent class analysis. Am J Trop Med Hyg. 2018;99(5):1174–9.CrossRef
17.
go back to reference Santos FL, Celedon PA, Zanchin NI, Leitolis A, Crestani S, Foti L, et al. Performance assessment of a Trypanosoma cruzi chimeric antigen in multiplex liquid microarray assays. J Clin Microbiol. 2017;55(10):2934–45.CrossRef Santos FL, Celedon PA, Zanchin NI, Leitolis A, Crestani S, Foti L, et al. Performance assessment of a Trypanosoma cruzi chimeric antigen in multiplex liquid microarray assays. J Clin Microbiol. 2017;55(10):2934–45.CrossRef
18.
go back to reference Santos FL, Celedon PA, Zanchin NI, Brasil TA, Foti L, Souza WV, et al. Performance assessment of four chimeric Trypanosoma cruzi antigens based on antigen-antibody detection for diagnosis of chronic Chagas disease. PLoS One. 2016;11(8):e0161100.CrossRef Santos FL, Celedon PA, Zanchin NI, Brasil TA, Foti L, Souza WV, et al. Performance assessment of four chimeric Trypanosoma cruzi antigens based on antigen-antibody detection for diagnosis of chronic Chagas disease. PLoS One. 2016;11(8):e0161100.CrossRef
19.
go back to reference Brito VS, Santos FL, Gonçalves NL, Araujo TH, Nascimento DS, Pereira FM, et al. Performance of commercially available serological screening tests for human T-cell lymphotropic virus infection in Brazil. J Clin Microbiol. 2018;56(12):e00961–18. Brito VS, Santos FL, Gonçalves NL, Araujo TH, Nascimento DS, Pereira FM, et al. Performance of commercially available serological screening tests for human T-cell lymphotropic virus infection in Brazil. J Clin Microbiol. 2018;56(12):e00961–18.
20.
go back to reference Leeflang MM, Allerberger F. How to: evaluate a diagnostic test. Clin Microbiol Infect. 2019;25(1):54–9.CrossRef Leeflang MM, Allerberger F. How to: evaluate a diagnostic test. Clin Microbiol Infect. 2019;25(1):54–9.CrossRef
21.
go back to reference Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6(11):e012799.CrossRef Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6(11):e012799.CrossRef
22.
go back to reference Tibayrenc M, Ayala FJ. Towards a population genetics of microorganisms: the clonal theory of parasitic protozoa. Parasitol Today. 1991;7(9):228–32.CrossRef Tibayrenc M, Ayala FJ. Towards a population genetics of microorganisms: the clonal theory of parasitic protozoa. Parasitol Today. 1991;7(9):228–32.CrossRef
23.
go back to reference Zingales B, Andrade SG, Briones MR, Campbell DA, Chiari E, Fernandes O, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz. 2009;104(7):1051–4.CrossRef Zingales B, Andrade SG, Briones MR, Campbell DA, Chiari E, Fernandes O, et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem Inst Oswaldo Cruz. 2009;104(7):1051–4.CrossRef
24.
go back to reference Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MM, et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol. 2012;12(2):240–53.CrossRef Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MM, et al. The revised Trypanosoma cruzi subspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol. 2012;12(2):240–53.CrossRef
25.
go back to reference Umezawa ES, Bastos SF, Camargo ME, Yamauchi LM, Santos MR, Gonzalez A, et al. Evaluation of recombinant antigens for serodiagnosis of Chagas’ disease in south and Central America. J Clin Microbiol. 1999;37(5):1554–60. Umezawa ES, Bastos SF, Camargo ME, Yamauchi LM, Santos MR, Gonzalez A, et al. Evaluation of recombinant antigens for serodiagnosis of Chagas’ disease in south and Central America. J Clin Microbiol. 1999;37(5):1554–60.
26.
go back to reference Umezawa ES, Bastos SF, Coura JR, Levin MJ, Gonzalez A, Rangel-Aldao R, et al. An improved serodiagnostic test for Chagas’ disease employing a mixture of Trypanosoma cruzi recombinant antigens. Transfusion. 2003;43(1):91–7.CrossRef Umezawa ES, Bastos SF, Coura JR, Levin MJ, Gonzalez A, Rangel-Aldao R, et al. An improved serodiagnostic test for Chagas’ disease employing a mixture of Trypanosoma cruzi recombinant antigens. Transfusion. 2003;43(1):91–7.CrossRef
27.
go back to reference Verani JR, Seitz A, Gilman RH, LaFuente C, Galdos-Cardenas G, Kawai V, et al. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection. Am J Trop Med Hyg. 2009;80(3):410–5.CrossRef Verani JR, Seitz A, Gilman RH, LaFuente C, Galdos-Cardenas G, Kawai V, et al. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection. Am J Trop Med Hyg. 2009;80(3):410–5.CrossRef
28.
go back to reference Martin DL, Marks M, Galdos-Cardenas G, Gilman RH, Goodhew B, Ferrufino L, et al. Regional variation in the correlation of antibody and T-cell responses to Trypanosoma cruzi. Am J Trop Med Hyg. 2014;90(6):1074–81.CrossRef Martin DL, Marks M, Galdos-Cardenas G, Gilman RH, Goodhew B, Ferrufino L, et al. Regional variation in the correlation of antibody and T-cell responses to Trypanosoma cruzi. Am J Trop Med Hyg. 2014;90(6):1074–81.CrossRef
29.
go back to reference Abras A, Gállego M, Muñoz C, Juiz NA, Ramírez JC, Cura CI, et al. Identification of Trypanosoma cruzi discrete typing units (DTUs) in Latin-American migrants in Barcelona (Spain). Parasitol Int. 2017;66(2):83–8.CrossRef Abras A, Gállego M, Muñoz C, Juiz NA, Ramírez JC, Cura CI, et al. Identification of Trypanosoma cruzi discrete typing units (DTUs) in Latin-American migrants in Barcelona (Spain). Parasitol Int. 2017;66(2):83–8.CrossRef
Metadata
Title
Immune reactivity to Trypanosoma cruzi chimeric proteins for Chagas disease diagnosis in immigrants living in a non-endemic setting
Authors
Eva Dopico
Rodrigo Pimenta Del-Rei
Bertha Espinoza
Itziar Ubillos
Nilson Ivo Tonin Zanchin
Elena Sulleiro
Zaira Moure
Paola Alejandra Fiorani Celedon
Wayner Vieira Souza
Edimilson Domingos da Silva
Yara Miranda Gomes
Fred Luciano Neves Santos
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-3872-z

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.